Tetratherix Reports First Product Revenue as FDA Seeks Further Tegenix Details
TTX: $5.50 +2.80% · MC: $340M
Tetratherix generated its first product revenue after shipping STEPP polymer to US partner Superpower Health, ahead of a planned launch next year. The FDA confirmed core elements of the Tegenix submission but requested further chemical characterisation and labelling details. The company ended the quarter with approximately $26 million in cash after an $8 million decrease, and said TetraDerm trial treatment was complete with results still blinded. Following Nexia’s resignation, BDO was appointed auditor, subject to shareholder approval at the upcoming AGM.

Comments